Novo Nordisk

Medical alert for insulin pen users issued

24th August 2017

A medical safety alert involving a greater risk of hypoglycaemia has been issued about a specific brand of insulin pen.  The Medicines and Healthcare Products Regulatory Agency has released ...

Read more

New £115m type 2 diabetes research centre

30th January 2017

A pioneering research centre aimed at finding new treatments for type 2 diabetes will be built as part of a £115m collaboration between Novo Nordisk and a leading university. Novo Nordisk has ...

Read more

GLP-1 cost-effectiveness study published

6th January 2017

Liraglutide 1.2 mg has proved “cost-effective” compared to alternative daily administered GLP-1 receptor agonists for the treatment of type 2 diabetes in the UK, a study has ...

Read more

Global diabetes child care programme extended

1st December 2016

A programme which provides children wth type 1 diabetes around the world free access to insulin and treatment has been extended. The Changing Diabetes® in Children initiative will continue for ...

Read more

Study shows Xultophy boosts glycaemic targets

21st September 2016

Adults with type 2 diabetes treated with Xultophy® (insulin degludec/liraglutide) are up to 4.5 times more likely to achieve glycaemic targets without hypoglycaemia and weight gain, research has ...

Read more